Bharat Biotech has said that its corona vaccine Covaxin is 77.8 percent effective against the symptotic infection of COVID-19. It is 93.4 percent effective against severe infections. This vaccine gives up to 65.2% protection against the delta variant of the corona. Bharat Biotech said on Saturday morning that in the final results of its Phase III clinical trial, Covaxin was found to be 77.8 percent effective against Corona. Last month, an expert panel of the Central Drugs Authority, while reviewing data from Bharat Biotech’s Phase-3 trial results, approved it.
Bharat Biotech said, the largest trial to test the efficacy of the vaccine
Covaccine is one of the three vaccines that the DGCI approved for use in emergency. The government is using it against COVID-19. Bharat Biotech has developed this vaccine in collaboration with ICMR and NIV Pune. Bharat Biotech has termed it as the largest trial to test its efficacy. The trial for Phase 3 took place from 16 November 2020 to 7 January 2021 and involved 25,798 people between the ages of 18 and 98.
Retailers and wholesalers again under the purview of MSME, the government withdrew the four-year-old decision
Emergency use approved in 16 countries including Brazil, Philippines
Covaccine has been approved for emergency use in 16 countries including Brazil, Philippines, Iran and Mexico. Bharat Biotech in talks with WHO for emergency use listing. It is expected that the Covaccine will be approved by the WHO soon. According to Medervix, the pre-print data of the efficacy of the vaccine has not yet been certified. Bharat Biotech says that it will prepare 23 million doses of Covaccine in a month.
Get Business News in Hindi, latest India News in Hindi, and other breaking news on share market, investment scheme and much more on Business Khabar. Like us on Facebook, Follow us on Twitter for latest financial news and share market updates.
.